Roman Butler Fullerton & Co’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
VCM
VPM
Roman Butler Fullerton & Co's LLY Position: Q1 2026 in Review
Roman Butler Fullerton & Co increased its Eli Lilly (LLY) stake by 0.45% in Q1 2026, buying an estimated $33.5K and bringing the position to 7,341 shares worth $7M. The position accounts for 1.92% of the portfolio, ranked #10.
Roman Butler Fullerton & Co first reported a position in LLY in Q4 2018 and has held it in 30 quarters since. The position peaked at $9.31M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Roman Butler Fullerton & Co held 7,341 shares of Eli Lilly worth $7M as of Q1 2026.
- Roman Butler Fullerton & Co bought 33 Eli Lilly shares in Q1 2026, an estimated $33.5K.
- Eli Lilly made up 1.92% of Roman Butler Fullerton & Co's portfolio in Q1 2026, its #10 holding.
- Roman Butler Fullerton & Co first reported a position in Eli Lilly in Q4 2018 and has held it in 30 quarters since.
- Roman Butler Fullerton & Co's Eli Lilly position peaked at $9.31M in Q2 2024.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Roman Butler Fullerton & Co's 13F filing for Q1 2026, filed 30 Apr 2026.